This year’s LESI conference focused on how licensing executives can best commercialise IP in a time of rapid technological change.
Andy Richards, a biotechnology entrepreneur and chairman and director of various Cambridge-based biotechnology companies, chaired a panel that looked at the challenges facing 21st century life sciences companies.
Richards said that many of the new technologies being invented do not fit current licensing business models. The life sciences market is further complicated by companies such as Google and Microsoft entering a market (through research funding) already populated by mainstays such as GE.
New business ventures from emerging markets may add to this because it is unclear “what form those will take”, he said.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
LESI conference 2011, life sciences, technology
